TA
Tarsons Products Ltd (TARSONS)
₹303.40
Mkt cap
₹1,614 Cr
P/E ratio
197.00
P/B
2.55
Div yield
0.00%
ROE
2.44%
ROCE
4.59%
EPS (TTM)
₹1.54
Book value
₹119
52W range
164–375
Sector
Healthcare
Price history
Previous close
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals [1]
NSE TARSONSBSE 543399
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−19.09% from high₹303
₹164+84.49% from low₹375
Current
₹303.40
Prev close
₹303.70
Day
−0.10%
Price performance
1D
−0.16%
1W
−3.88%
1M
−1.77%
3M
−10.11%
6M
+43.68%
1Y
+26.49%
YTD
+28.97%
Financials
Revenue, profit & margin
P/E ratio
197.0×
TARSONS is 434% above the sector median of 36.9×
TARSONS197.0×
Sector median36.9×
| Mar 2022 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 84.94 | 61.79 | 105.72 | 84.80 | 99.25 | 95.68 | 112.69 | 91.36 | 102.33 | 107.89 | 120.93 | 110.24 | 123.65 | |
| YoY Sales growth | +25.73% | +54.85% | +6.59% | +7.74% | +3.10% | +12.76% | +7.31% | +20.67% | +20.83% | |||||
| Expenses | 40.61 | 38.91 | 75.48 | 66.04 | 73.94 | 66.04 | 75.67 | 66.66 | 74.88 | 76.37 | 86.66 | 84.25 | 92.55 | |
| Operating Profit | 44.33 | 22.88 | 30.24 | 18.76 | 25.31 | 29.64 | 37.02 | 24.70 | 27.45 | 31.52 | 34.27 | 25.99 | 31.10 | |
| OPM % | 52.19% | 37.03% | 28.60% | 22.12% | 25.50% | 30.98% | 32.85% | 27.04% | 26.82% | 29.21% | 28.34% | 23.58% | 25.15% | |
| Other Income | 2.58 | 3.24 | 3.38 | 2.91 | 8.43 | 0.85 | 3.78 | 3.34 | 5.80 | 7.07 | 6.83 | 5.98 | 4.43 | |
| Interest | 0.45 | 2.51 | 4.25 | 4.32 | 4.84 | 5.03 | 5.20 | 5.07 | 5.18 | 6.05 | 6.25 | 6.27 | 6.60 | |
| Depreciation | 7.24 | 10.06 | 12.33 | 11.03 | 14.03 | 17.41 | 20.03 | 19.94 | 22.48 | 25.04 | 29.08 | 27.02 | 28.26 | |
| Profit before tax | 39.22 | 13.55 | 17.04 | 6.32 | 14.87 | 8.05 | 15.57 | 3.03 | 5.59 | 7.50 | 5.77 | -1.32 | 0.67 | |
| Tax % | 24.89% | 26.72% | 39.50% | 36.39% | 30.80% | 34.66% | 34.49% | 41.25% | 40.61% | 32.93% | 27.56% | 9.09% | 150.75% | |
| Net Profit | 29.46 | 9.93 | 10.32 | 4.02 | 10.29 | 5.26 | 10.20 | 1.78 | 3.32 | 5.04 | 4.18 | -1.44 | -0.34 | |
| EPS in Rs | 5.54 | 1.87 | 1.94 | 0.76 | 1.93 | 0.99 | 1.92 | 0.33 | 0.62 | 0.95 | 0.79 | -0.27 | -0.06 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202647.30%Promoter
Promoters47.30%
FIIs0.55%0.40
DIIs0.61%0.51
Public51.53%0.91
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnosti | ₹1,495.50 | 237.68 | 17,234 | 0.00% | 8 | −86.23% | 259 | −55.36% | 18.48% |
| Poly Medicure | ₹1,635.70 | 52.46 | 16,580 | 0.21% | 95 | −4.31% | 581 | +30.79% | 12.50% |
| Sahajanand Medi | ₹527.60 | 74.68 | 5,363 | 0.00% | 26 | +32.12% | 373 | +24.69% | 11.35% |
| Tarsons Products | ₹303.40 | 197.34 | 1,614 | 0.00% | 0 | −110.24% | 124 | +20.83% | 4.59% |
| Fischer Medical | ₹22.33 | 137.10 | 1,560 | 0.22% | 1 | −94.22% | 107 | +24.50% | 11.45% |
| Laxmi Dental | ₹187.57 | 28.45 | 1,032 | 0.00% | 10 | +17.58% | 80 | +10.03% | 15.05% |
| Q-Line Biotech | ₹396.80 | 16.91 | 926 | 0.00% | 20 | −8.07% | 152 | +5.83% | 22.45% |
| Median: 18 Co. | ₹302.90 | 36.92 | 664 | 0.00% | 5 | −6.19% | 83 | +17.91% | 15.05% |
Filings
Annual reports5
Concall transcripts54
TranscriptNov 2026PPTNov 2026RECNov 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 19 Nov - Transcript of Nov 13 Q2/H1 FY27 earnings call; Q2 standalone revenue crossed ₹100 crore, up 25% YoY.Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Nov - Newspaper Publication of Financial Results for the quarter and half year ended September 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 13 Nov - Audio recording of 13 Nov 2026 investor conference call for Q2 FY27 results uploaded.Announcement under Regulation 30 (LODR)-Investor Presentation 13 Nov - Investor Presentation for the quarter and half year ended September 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Nov
